CN107115483A - It is a kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia and its application - Google Patents
It is a kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia and its application Download PDFInfo
- Publication number
- CN107115483A CN107115483A CN201710355881.2A CN201710355881A CN107115483A CN 107115483 A CN107115483 A CN 107115483A CN 201710355881 A CN201710355881 A CN 201710355881A CN 107115483 A CN107115483 A CN 107115483A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- myasthenia
- fruit
- muscular dystrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Muscular dystrophy, the pharmaceutical composition of myasthenia and its application are treated the invention belongs to a kind of；The pharmaceutical composition is formulated comprising following raw materials according：Dogwood fruit, the fruit of Chinese wolfberry, RADIX POLYGONI MULTIFLORI PREPARATA, cape jasmine, reticulate millettia, the membrane of a chicken's gizzard and Fructus Hordei Germinatus；Low with cost, treatment treatment muscular dystrophy, myasthenia effect are good, and Quality Control is stable, Nantural non-toxic, effect stability and the advantage suitable for long-term taking.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia
And its application.
Background technology
Muscular dystrophy, the disease of myasthenia, are the diseases that can be cured without medicine in the world at present, and modern medicine thinks the category heredity of this disease
Property disease, patient is more in the existing symptom of 3-5 annual expenditures, engenders abnormal gait, walking is waved, is commonly called as duck step, difficult upstairs, squats down
Dystasia, patient is often first stood up in dorsal position when getting up from horizontal position, is first come back, and knee, thigh are helped with both hands, slow straight
Trunk is stood, and when often families of patients is sought medical advice with infant to large hospital at present, doctor can tell him to treat this sick medicine to mesh
Before untill do not develop also, parents of hospitalized children can only go home to look at conditions of patients one day exacerbation in one day, it may appear that hand can not be held
Thing, foot can not appoint ground, pharynx food of dehiscing what is more, open eyes all highly difficult, or with diseases such as muscular atrophies, applicant is from traditional Chinese medical science angle
Think this disease category inadequate natural endowment, liver-kidney deficiency involves taste, liver governing tendons, liver hinders then four limbs and do not used for people, and muscle arteries and veins contraction, kidney
Store essential substances, essence and blood alternate, essence wound can not irrigate the tip of four limbs, and essence loses the then deficiency of blood, and the deficiency of blood is unable to nutrition muscles and bones, and stomach is paddy sea, is
The length of penis, taste operating is not good, then essence and blood metaplasia is not enough, or because of the occlusion of damp and hot turbid pathogenic factor, it is wet to multiply under, cause liver kidney taste
Dereliction of duty, gradually becomes this disease.
The content of the invention
It is an object of the invention to overcome defect of the prior art there is provided a kind of cost is low, myotrophy is treated not
Good, myasthenia effect is good, and Quality Control is stable, and Nantural non-toxic, effect stability and one kind suitable for long-term taking treat myotrophy not
Good, myasthenia pharmaceutical composition and its application.
The object of the present invention is achieved like this：The pharmaceutical composition is formulated comprising following raw materials according：Dogwood fruit, matrimony vine
Son, RADIX POLYGONI MULTIFLORI PREPARATA, cape jasmine, reticulate millettia, the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：20~46 parts of dogwood fruit, 12~30 parts of the fruit of Chinese wolfberry, 10~40 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10~15 parts of cape jasmine, chicken blood
25~35 parts of 10~20 parts of rattan, 10~20 parts of the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：25~37 parts of dogwood fruit, 16~24 parts of the fruit of Chinese wolfberry, 18~25 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10~13 parts of cape jasmine, chicken blood
28~30 parts of 15~19 parts of rattan, 15~19 parts of the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：36 parts of dogwood fruit, 23.5 parts of the fruit of Chinese wolfberry, 18 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 12 parts of cape jasmine, 18 parts of reticulate millettia, the membrane of a chicken's gizzard
16 parts and 28 parts of Fructus Hordei Germinatus.
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：30 parts of dogwood fruit, 18 parts of the fruit of Chinese wolfberry, 20 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10 parts of cape jasmine, 15 parts of reticulate millettia, the membrane of a chicken's gizzard 15
30 parts of part and Fructus Hordei Germinatus.
The invention provides aforementioned pharmaceutical compositions in treatment muscular dystrophy, the pharmaceutical composition of myasthenia is prepared
Using.
Heretofore described dogwood fruit, the fruit of Chinese wolfberry, RADIX POLYGONI MULTIFLORI PREPARATA, cape jasmine, reticulate millettia, the membrane of a chicken's gizzard and Fructus Hordei Germinatus can be direct
By being commercially available.The present invention decoction or can pulverize and sieve above-mentioned raw materials respectively by weight, mix, and load capsule or pressure
It is made as tablet；Or mixed with pharmaceutically acceptable carrier or diluent, it is reloaded into capsule or is compressed to tablet.
Present invention is mainly used for treatment muscular dystrophy, myasthenia, by taking decoction as an example, per the decoction of pair Chinese medicine twice, one day
Once, one month be a course for the treatment of, it is necessary to continuously take six to eight courses for the treatment of；Especially, it need to be abided by when the special population such as pregnant woman is taken
Doctor's advice, not yet finds its special adverse reaction at present.Treatment of the present invention means the treatment after morbidity, does not represent premorbid
Intervention.
Present invention RADIX POLYGONI MULTIFLORI PREPARATA, dogwood fruit, fruit of Chinese wolfberry filling liver kidney, benefiting essence-blood, strengthening the bones and muscles, puckery vital essence, collapse admittedly, change turbid drop
It is wet to mend congenital deficiency as monarch, with the membrane of a chicken's gizzard, Fructus Hordei Germinatus regulating spleen and stomach, be qi and blood it is biochemical it is active be minister；Cape jasmine clearing heat and promoting diuresis,
Clear liver and improve vision, it is not assistant by damp and hot puzzlement to make muscles and bones, and reticulate millettia replenishing and activating blood degrading the channel is makes, the emphasis in the technical program
It is reusing the membrane of a chicken's gizzard, Fructus Hordei Germinatus regulating spleen and stomach, is that qi and blood biochemistry is active, qi and blood is biochemical continually, and muscles and bones is nourished
The channels and collaterals of the through four limbs of essence and blood, two hands obtain blood and can then held, and two foots obtain blood and can then manage it, and this disease can just fully recover rapidly.
Dogwood fruit：Sour, puckery, tepor.Major function：Tonify the liver and kidney, puckery smart hidroschesis：For kidney deficiency and liver the soreness of waist seminal emission,
Have a dizzy spell, the disease such as menorrhalgia and frequent micturition, spontaneous perspiration.
The fruit of Chinese wolfberry：It is sweet, put down；Return liver and kidney channel.It is nourishing liver and kidney, benefiting shrewd head.The rich in nutrition content of matrimony vine, is current battalion
Support comprehensive natural material.Must containing human bodies such as substantial amounts of protein, amino acid, vitamin and iron, zinc, phosphorus, calcium in the fruit of Chinese wolfberry
The nutritional ingredient needed, has promotion and regulation immunologic function, liver protection and the big pharmacological action of anti-aging three, with not replaceable medicinal
Value.LBP-X is one of composition of most important most critical in matrimony vine, can promote the phagocytic activity of peritoneal macrophage, to people
The reparation that body, which has, to be improved metabolism, regulation endocrine, promote protein synthesis, accelerate liver detoxification and wounded hepatocytes,
Suppress the function of cholesterol and triglycerides, and have obvious protection and repair to the lipid peroxidation injury of liver.
Have effects that strong smart, the nourishing liver and kidney, anti-aging of tonifying Qi, only quench one's thirst, warming up body.
RADIX POLYGONI MULTIFLORI PREPARATA：This product is in the block piece of irregular shrunk, thickness about 1cm.Surface dark brown or sepia, it is uneven.
Matter is hard, section cutin sample, sepia or black.Gas is micro-, taste micro-sweet and it is pained.Major function：Filling liver kidney, benefiting essence-blood, black palpus
Turbid lipid-loweringing is changed in hair, strengthening the bones and muscles.For blood deficiency chlorosis, dizziness ear toot, poliosis, soreness and weakness of waist and knees, extremity numbness, under uterine bleeding band,
Hyperlipidemia.
Cape jasmine：Hardship, trembles with fear.Enter the heart, liver, lung, stomach.Major function：Heat-clearing, purging intense heat, cool blood.Pyreticosis restlessness of asrhenia type and insomnia is controlled, it is yellow
Subcutaneous ulcer, gonorrhoea is quenched one's thirst, hot eyes, pharyngalgia, is spitted blood, and bleeding from five sense organs or subcutaneous tissue, bloody flux, hematuria, pathopyretic ulcer is sprained and swollen and ache.
Reticulate millettia：Bitter；Micro-sweet；It is warm-natured.The heart channel of Hang-Shaoyin；The spleen channel.Cure mainly：Activate blood and relax tendons；Nourishing blood for regulating menstruation.Master is numb in every limb；Limb
Body is paralysed；Arthralgia pain due to rheumatism；Women has through uncomfortable；Dysmenorrhoea；Amenorrhoea.Function：Enrich blood, invigorate blood circulation, dredging collateral.For irregular menstruation, the deficiency of blood
It is sallow, paralysis and numbness, arthralgia pain due to rheumatism.
The membrane of a chicken's gizzard：It is sweet, tremble with fear；Returns spleen, stomach, small intestine, bladder warp；Major function：Disperse accumulations is stagnant, strengthening the spleen and stomach.Dyspepsia turgor is controlled, is vomitted
Gastric disorder causing nausea is told, rush down dysentery, infantile malnutrition due to digestive disturbances or intestinalparasites is quenched one's thirst, lose and drown, larynx numbness acute tonsillitis, noma aphtha.
Fructus Hordei Germinatus：It is sweet, put down.Returns spleen, stomach.Effect：Promoting the circulation of qi helps digestion, spleen benefiting and stimulating the appetite, moves back newborn dissipate-swelling.Cure mainly：Dyspepsia,
Abdominal distention, spleen eating less, newborn sweat smoulders, swollen breasts, women weans.
The present invention has cost low, and treatment treatment muscular dystrophy, myasthenia effect are good, and Quality Control is stable, Nantural non-toxic, effect
Fruit is stable and suitable for the advantage of long-term taking.
Embodiment
The present invention treats muscular dystrophy, the pharmaceutical composition of myasthenia and its application to be a kind of；The pharmaceutical composition bag
It is formulated containing following raw materials according：Dogwood fruit, the fruit of Chinese wolfberry, RADIX POLYGONI MULTIFLORI PREPARATA, cape jasmine, reticulate millettia, the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：20~46 parts of dogwood fruit, 12~30 parts of the fruit of Chinese wolfberry, 10~40 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10~15 parts of cape jasmine, chicken blood
25~35 parts of 10~20 parts of rattan, 10~20 parts of the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：25~37 parts of dogwood fruit, 16~24 parts of the fruit of Chinese wolfberry, 18~25 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10~13 parts of cape jasmine, chicken blood
28~30 parts of 15~19 parts of rattan, 15~19 parts of the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：36 parts of dogwood fruit, 23.5 parts of the fruit of Chinese wolfberry, 18 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 12 parts of cape jasmine, 18 parts of reticulate millettia, the membrane of a chicken's gizzard
16 parts and 28 parts of Fructus Hordei Germinatus.
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：30 parts of dogwood fruit, 18 parts of the fruit of Chinese wolfberry, 20 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10 parts of cape jasmine, 15 parts of reticulate millettia, the membrane of a chicken's gizzard 15
30 parts of part and Fructus Hordei Germinatus.
The invention provides aforementioned pharmaceutical compositions in treatment muscular dystrophy, the pharmaceutical composition of myasthenia is prepared
Using.
In order to more clearly explain the present invention, it is further described in conjunction with specific embodiment.It is specific real
Under applying for example：
Embodiment one
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：47 parts of dogwood fruit, 31 parts of the fruit of Chinese wolfberry, 42 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 9 parts of cape jasmine, 9 parts of reticulate millettia, 15 parts of the membrane of a chicken's gizzard
With 24.5 parts of Fructus Hordei Germinatus.
Embodiment two
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：48 parts of dogwood fruit, 25 parts of the fruit of Chinese wolfberry, 40 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 16 parts of cape jasmine, 21 parts of reticulate millettia, 9 parts of the membrane of a chicken's gizzard
With 36 parts of Fructus Hordei Germinatus.
Embodiment three
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：20 parts of dogwood fruit, 12 parts of the fruit of Chinese wolfberry, 10 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10 parts of cape jasmine, 10 parts of reticulate millettia, the membrane of a chicken's gizzard 10
25 parts of part and Fructus Hordei Germinatus.
Example IV
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：46 parts of dogwood fruit, 30 parts of the fruit of Chinese wolfberry, 40 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 15 parts of cape jasmine, 20 parts of reticulate millettia, the membrane of a chicken's gizzard 20
35 parts of part and Fructus Hordei Germinatus.
Embodiment five
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：33 parts of dogwood fruit, 21 parts of the fruit of Chinese wolfberry, 25 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 12.5 parts of cape jasmine, 15 parts of reticulate millettia, the membrane of a chicken's gizzard
15 parts and 30 parts of Fructus Hordei Germinatus.
Embodiment six
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：25 parts of dogwood fruit, 16 parts of the fruit of Chinese wolfberry, 18 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10 parts of cape jasmine, 15 parts of reticulate millettia, the membrane of a chicken's gizzard 15
28 parts of part and Fructus Hordei Germinatus.
Embodiment seven
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：37 parts of dogwood fruit, 24 parts of the fruit of Chinese wolfberry, 25 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 13 parts of cape jasmine, 19 parts of reticulate millettia, the membrane of a chicken's gizzard 19
30 parts of part and Fructus Hordei Germinatus.
Embodiment eight
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：31 parts of dogwood fruit, 20 parts of the fruit of Chinese wolfberry, 21.5 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 11.5 parts of cape jasmine, 17 parts of reticulate millettia, in chicken
29 parts of 17 parts of gold and Fructus Hordei Germinatus.
Embodiment nine
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：36 parts of dogwood fruit, 23.5 parts of the fruit of Chinese wolfberry, 18 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 12 parts of cape jasmine, 18 parts of reticulate millettia, the membrane of a chicken's gizzard
16 parts and 28 parts of Fructus Hordei Germinatus.
Embodiment ten
A kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia, the pharmaceutical composition is comprising following raw materials according according to weight
Amount number is formulated：30 parts of dogwood fruit, 18 parts of the fruit of Chinese wolfberry, 20 parts of RADIX POLYGONI MULTIFLORI PREPARATA, 10 parts of cape jasmine, 15 parts of reticulate millettia, the membrane of a chicken's gizzard 15
30 parts of part and Fructus Hordei Germinatus.
Above-described embodiment is only intended to clearly illustrate example of the present invention, and the not restriction to embodiment.
For the general technical staff of art, other various forms of changes can also be made on the basis of the above description
Or change.There is no necessity and possibility to exhaust all the enbodiments, and the obvious change thus amplified out
Or among changing still in the invention scope of the claims.
Case 1：Beam, female, 40 years old, Dengzhou City dragon weir village people.Powerless, the walking that double lower limb occurs without obvious inducement in 2009
Still, after because double lower limb it is powerless aggravate walking step state walk haltingly it is medical.Then go to a doctor in affiliated hospital of Medical College of Zhejiang Univ., improve phase
Inspection is closed to be diagnosed as：" polymyositis " " lumbar intervertebral disc bulge disease " hospitalization, which takes a turn for the better, leaves hospital.It is interrupted oral western medicine after discharge
Unsatisfactory curative effect is treated, checks that myocardial enzymes show * AST60U/L, LDH518U/ in Nanyang First People's Hospital in May, 2013
L, HBDH343U/L, CK3442U/L, CK-MB109U/L.July in the same year is shown in Zhejiang Su Shan examination in hospital myocardial enzymes
AST175.4U/L, LDH752.3U/L, CK7976.1U/L, CK-MB212U/L.It is interrupted oral traditional Chinese medicine treatment, it is invalid, in 2016
March in year goes to a doctor and improves coherence check in Shanghai City Jing'an District central hospital, and (muscle) pathological diagnosis is shown：Limb girdle type myotrophy is not
It is good, IIB types.Electromyogram report diagnostic shows：Myopathic lesion myoelectricity changes.Radiodiagnosis is shown：The different journeys of each muscle group of bilateral shank
Atrophy is spent with fatty infiltration.Oral drug therapy is given, the state of an illness does not improve, it is to our hospital before further treatment to ask, look into
Blood routine shows：Leucocyte 2.5 × 109/ L, red blood cell 3.8 × 1012/ L, hemoglobin 111g/L, blood platelet 169 × 109/L.Examine
It is disconnected：Muscular dystrophy.Syndrome Types of TCM：Liver-kidney deficiency, stagnation of damp-heat.The rules for the treatment of：Flat filling liver kidney, dampness removing heat-clearing.Using of the invention real
Apply example nine to be treated, instructions of taking：It is decocted in water for oral dose, one portion per day, six courses for the treatment of of continuously taking medicine, electromyogram diagnosis is shown：Before double shins
Flesh, left quadriceps have no obvious Myopathic lesion and neurogenic urinary incontinence, and double lower limb walking is strong, can stair climbing alone,
Daily life is such as ordinary person.
Case 2：Rather certain, male, 8 years old, Dengzhou City Tuan He people from subdistrict offices.In August, 2013 is without under the appearance pair of obvious inducement
Myasthenia of limbs, can still walk but walking is walked haltingly.Cranium brain CT examination is carried out to Dengzhou City institute of traditional Chinese medicine to show：Brain parenchym is shown no obvious abnormalities,
Do not treat.Lumbar vertebrae MRI was carried out on 2 10th, 2014 to Nanyang central hospital：Show no obvious abnormalities.Myoelectricity is illustrated：Bilateral calf
Nerve and nervus tibialis are abnormal.Arrive affiliated hospital of Zhengzhou University the 3rd and look into sero-enzyme and show：AST447U/L, ASTM89U/L,
CK34310U/L, CK-MB1200U/L, LDH2232U/L, HBDH1486U/L.Peking University first was arrived on 2 28th, 2014
Hospital does coherence check and shown：ALT*135U/L, AST*147U/L, LDH*1006U/L, HBDH782U/L, CK* ＞ 8000U/L,
CK-MB ＞ 308ng/ml.Inherited myopathy testing result is shown：It was found that person under inspection's DMD gene 48-50 exon deletion mutations.
Do not find that its female DMD gene of person under inspection has large fragment variation.It is diagnosed as：Muscular dystrophy, gives prednisone acetate piece
15mgBid is oral, DeGrain.Nearly eight months symptoms are gradually aggravated, and are developed to powerless upstairs.To ask further treatment to come
Our hospital goes to a doctor.Diagnosis：Muscular dystrophy.Syndrome Types of TCM：Liver-kidney deficiency, stagnation of damp-heat.The rules for the treatment of：Flat filling liver kidney, dampness removing heat-clearing.Adopt
Treated with the embodiment of the present invention six, instructions of taking：It is decocted in water for oral dose, one portion per day, continuously eight courses for the treatment of of medication, check serum
Enzyme：CK184IU/L, CK-MB ＜ 5ng/ml.Myoelectricity is illustrated：Bilateral nervus peronaeus and nervus tibialis are shown no obvious abnormalities.In more than 2016
Secondary check sero-enzyme is in normal range (NR), and double lower limb is strong, can normally walk.
Case 3：Huang, man, 5 years old, Hubei Xiaogan people.Patient has found transaminase when in August, 2010 suffers from hand-foot-and-mouth disease
Height, is subsequently found CK1087U/L, electromyogram no abnormality seen is gone to a doctor in hospital of Tongji University of Hubei Province then, true by improving coherence check
Examine as " myasthenia gravis ", shakiness of walking at that time needs hand steered knee during squatting up, muscular strength reduction uses medicine, massaging and physiotherapeutical always
Deng treatment, effect is undesirable, and the present further treats to our hospital to ask.Our hospital improves after coherence check and is diagnosed as：Myotrophy
It is bad.Syndrome Types of TCM：Liver-kidney deficiency, stagnation of damp-heat.The rules for the treatment of：Flat filling liver kidney, dampness removing heat-clearing is carried out using the embodiment of the present invention three
Treatment, instructions of taking：It is decocted in water for oral dose, one portion per day, continuously ten courses for the treatment of of medication, check sero-enzyme：CK86IU/L, CK-MB ＜
5ng/ml.Myoelectricity is illustrated：Show no obvious abnormalities.In 2015, repeatedly check sero-enzyme, in normal range (NR), was now walked normal, under
Squatting up without hand steered knee, can normally go to school immediately.
The clinical test carried out with reference to our hospital, i.e. Henan Dengzhou City Zhen Yu blood diseases hospital makees further to the present invention
Ground is illustrated：
1. case selection：Selected case is our hospital muscular dystrophy patient, selection muscular dystrophy patient 39, man 26
Example, female 13；The course of disease 30 days to 10 months；Duchenne muscular dystrophy 23, limb girdle type muscular dystrophy 16.
2. diagnostic criteria：According to State Administration of Traditional Chinese Medicine, Chinese medical disease Standardization of diagnosis and curative effect, the state of an illness according to patient,
Sero-enzyme, electromyogram are made a definite diagnosis.
3. treatment method：The daily instructions of taking according to the present invention is taken, and warmly takes 150ml on an empty stomach every time, is within one month one
The course for the treatment of, interval 4 days, then next course for the treatment of is carried out, and six courses for the treatment of are typically continuously taken, are disappeared to Clinical symptom and sign, chemical examination
Check it is normal after, then consolidate curative effect and take two courses for the treatment of, and follow-up in 3 months is once.
4. the standard of curative effect evaluation：
(1) it is basic to cure：Clinical myasthenia symptom and sign disappears, and laboratory examination sero-enzyme is normal, electromyography without
Abnormal, follow-up 1 year is without recurrence.
(2) alleviate：Clinical myasthenia symptom disappears substantially, and laboratory examination sero-enzyme is higher, and electromyography is without exception.
6 months stable diseases of follow-up are without recurrence.
(3) it is substantially progressive：Clinical myasthenia symptom and sign is clearly better, and laboratory examination sero-enzyme is higher, electromyogram inspection
Look into and be clearly better.3 months stability and no relapses of follow-up.
(4) it is invalid：After treating six courses for the treatment of, Clinical symptom and sign is not improved, laboratory examination sero-enzyme, myoelectricity
Figure is without substantially progressive.
5. therapeutic effect：Clinical 39 muscular dystrophy patients, which are applied to, using the present invention treats six courses for the treatment of, it is extremely clinical
Symptom and sign disappears, after laboratory examination is normal, then consolidates curative effect and take two courses for the treatment of, carries out controlling curative effect using the standard of curative effect evaluation
Fruit is evaluated：It is basic to cure 25, account for 64.1%；Alleviate 9, account for 23%；It is substantially progressive 3, account for 7.7%；Invalid 2
Example, accounts for 5.1%.Total effective rate is about 94.9%, and heretofore described effectively refers to basic healing, alleviates and substantially enter
Step.
Claims (6)
1. a kind of treat muscular dystrophy, the pharmaceutical composition of myasthenia, it is characterised in that：The pharmaceutical composition includes following original
Material is formulated：Dogwood fruit, the fruit of Chinese wolfberry, RADIX POLYGONI MULTIFLORI PREPARATA, cape jasmine, reticulate millettia, the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
2. a kind of muscular dystrophy, the pharmaceutical composition of myasthenia are treated according to claim 1, it is characterised in that：Should
Pharmaceutical composition is formulated comprising following raw materials according according to parts by weight：20~46 parts of dogwood fruit, 12~30 parts of the fruit of Chinese wolfberry, system are first
25~35 parts of 10~40 parts of crow, 10~15 parts of cape jasmine, 10~20 parts of reticulate millettia, 10~20 parts of the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
3. a kind of muscular dystrophy, the pharmaceutical composition of myasthenia are treated according to claim 1, it is characterised in that：Should
Pharmaceutical composition is formulated comprising following raw materials according according to parts by weight：25~37 parts of dogwood fruit, 16~24 parts of the fruit of Chinese wolfberry, system are first
28~30 parts of 18~25 parts of crow, 10~13 parts of cape jasmine, 15~19 parts of reticulate millettia, 15~19 parts of the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
4. a kind of muscular dystrophy, the pharmaceutical composition of myasthenia are treated according to claim 1, it is characterised in that：Should
Pharmaceutical composition is formulated comprising following raw materials according according to parts by weight：36 parts of dogwood fruit, 23.5 parts of the fruit of Chinese wolfberry, RADIX POLYGONI MULTIFLORI PREPARATA 18
28 parts of part, 12 parts of cape jasmine, 18 parts of reticulate millettia, 16 parts of the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
5. a kind of muscular dystrophy, the pharmaceutical composition of myasthenia are treated according to claim 1, it is characterised in that：Should
Pharmaceutical composition is formulated comprising following raw materials according according to parts by weight：30 parts of dogwood fruit, 18 parts of the fruit of Chinese wolfberry, 20 parts of RADIX POLYGONI MULTIFLORI PREPARATA,
30 parts of 10 parts of cape jasmine, 15 parts of reticulate millettia, 15 parts of the membrane of a chicken's gizzard and Fructus Hordei Germinatus.
6. a kind of pharmaceutical composition as described in claim 1-5 is preparing the drug regimen for the treatment of muscular dystrophy, myasthenia
Application in thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710355881.2A CN107115483B (en) | 2017-05-02 | 2017-05-02 | Pharmaceutical composition for treating muscular dystrophy and myasthenia and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710355881.2A CN107115483B (en) | 2017-05-02 | 2017-05-02 | Pharmaceutical composition for treating muscular dystrophy and myasthenia and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107115483A true CN107115483A (en) | 2017-09-01 |
| CN107115483B CN107115483B (en) | 2020-09-29 |
Family
ID=59727952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710355881.2A Active CN107115483B (en) | 2017-05-02 | 2017-05-02 | Pharmaceutical composition for treating muscular dystrophy and myasthenia and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107115483B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526389A (en) * | 2012-03-09 | 2012-07-04 | 王利伟 | Traditional Chinese medicine for treating myasthenia gravis and amyotrophy |
| CN104147456A (en) * | 2014-08-27 | 2014-11-19 | 中南林业科技大学 | Decoction for treating ocular myasthenia gravis |
| CN104740189A (en) * | 2014-06-19 | 2015-07-01 | 金华职业技术学院 | Traditional Chinese medicine composition for treating myasthenia gravis caused by deficiency of liver-yin and kidney-yin |
| CN105535448A (en) * | 2016-03-07 | 2016-05-04 | 乞国艳 | Traditional Chinese medicine composition for treating child myasthenia gravis |
-
2017
- 2017-05-02 CN CN201710355881.2A patent/CN107115483B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526389A (en) * | 2012-03-09 | 2012-07-04 | 王利伟 | Traditional Chinese medicine for treating myasthenia gravis and amyotrophy |
| CN104740189A (en) * | 2014-06-19 | 2015-07-01 | 金华职业技术学院 | Traditional Chinese medicine composition for treating myasthenia gravis caused by deficiency of liver-yin and kidney-yin |
| CN104147456A (en) * | 2014-08-27 | 2014-11-19 | 中南林业科技大学 | Decoction for treating ocular myasthenia gravis |
| CN105535448A (en) * | 2016-03-07 | 2016-05-04 | 乞国艳 | Traditional Chinese medicine composition for treating child myasthenia gravis |
Non-Patent Citations (4)
| Title |
|---|
| 倪鑫等: "《儿科》", 31 October 2014, 中国医药科技出版社 * |
| 李七一: "《难治性心脑血管病辩治与验案》", 28 February 2011, 科学技术文献出版社 * |
| 胡旭: "姜良铎教授应用胚芽类中药治疗疑难病举隅", 《新中医》 * |
| 颜学桔等: "刘光宪辨治重症肌无力经验", 《上海中医药杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107115483B (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104606513B (en) | A kind of Chinese medicine for treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN107693767A (en) | A kind of external medicine composition, its preparation method and application for preventing and treating diabetes | |
| CN104547822A (en) | Traditional Chinese medicinal composition for treating child enuresis and preparation method of preparations thereof | |
| CN100544761C (en) | A kind of medicine for the treatment of coronary heart disease | |
| CN108030859A (en) | It is a kind of to be used to treat Chinese medicine preparation of cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN107115483A (en) | It is a kind of to treat muscular dystrophy, the pharmaceutical composition of myasthenia and its application | |
| CN102552755B (en) | Traditional Chinese medicine composition for treating aplastic anemia | |
| CN110339323A (en) | A kind of Chinese medicine composition and its preparation method and application for treating bradycardia | |
| CN104740404A (en) | Traditional Chinese medicine composition for treating lupus erythematosus | |
| CN107929644A (en) | A kind of Chinese medicine composition for treating sinus bradycardia and preparation method thereof | |
| CN102872287A (en) | Traditional Chinese medicine composition for treating femoral head necrosis and preparation method thereof | |
| CN107929617A (en) | Treat Chinese medicine composition, pill of tuberculosis of bone and joint and preparation method thereof | |
| CN103341015B (en) | Medicine for treating three-highs and preparation method thereof | |
| CN102552443A (en) | Traditional Chinese drug composition for treating rheumatoid arthritis, and preparation method thereof | |
| CN100569252C (en) | The medicine and the preparation method of treatment essential hypertension | |
| CN107441180B (en) | Bone-strengthening traditional Chinese medicine composition and preparation method thereof | |
| CN106822852A (en) | Treat pharmaceutical composition, its preparation technology and the purposes of coronary heart disease | |
| CN101347494A (en) | Health products for preventing and treating women's climacteric syndrome | |
| CN107625863B (en) | Compound traditional Chinese medicine soft capsule for treating rheumatism bone disease and preparation method thereof | |
| CN104840814A (en) | Traditional Chinese medicine combination for treating senile femoral head necrosis | |
| CN105770687A (en) | Preparation method and application of anorexia patch | |
| CN104645244A (en) | Traditional Chinese medicine composition for treating atherosclerosis | |
| CN102641472B (en) | Chinese herbal preparation for curing osteoporosis | |
| CN105412322A (en) | Traditional Chinese medicine preparation for treating diabetic peripheral neuropathic pain and preparation method thereof | |
| CN104547989A (en) | Tibetan paste for treating spondylodynia and using method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |